Pluronic lecithin organogel

Article Sidebar

PDF
Published: Aug 25, 2014
DOI: https://doi.org/10.22377/ajp.v2i3.182

Main Article Content

Veena S Belgamwar
Mohit S Pandey
Dhiraj S Chauk
Sanjay J Surana

Abstract

The purpose of this review is to give detail insight of pluronic lecithin organogels (PLOs) as a topical and transdermal drug delivery system. Pluronic lecithin organogel is a microemulsion-based gel that has been effectively used by physicians and pharmacists to deliver hydrophilic and lipophilic drugs topically and transdermally across the stratum corneum. It is thermodynamically stable, viscoelastic, and biocompatible gel composed of phospholipids (lecithin), organic solvent, and polar solvent. Various types of therapeutic agents have been easily incorporated in PLO to improve their topical drug delivery. Pluronic lecithin organogel improves the topical administration of drug mainly because of desired drug partitioning, biphasic drug solubility, and the modification of skin barrier system by organogel components. Beside this, it shows low skin
irritation, increases patient compliance, reduces side effects, avoids first pass metabolism, and increases efficiency of drug. In addition, PLO has been shown in vivo and in vitro to modulate the release and permeation of drugs applied transdermally. Thus, in future, it has wide range of applications and opportunities to experiment with various drugs in this type of drug
delivery system.

Downloads

Download data is not yet available.

Article Details

How to Cite
Belgamwar, V. S., Pandey, M. S., Chauk, D. S., & Surana, S. J. (2014). Pluronic lecithin organogel. Asian Journal of Pharmaceutics (AJP), 2(3). https://doi.org/10.22377/ajp.v2i3.182
Issue
Vol. 2 No. 3 (2008): Jul-Sep
Section
Articles

This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.

References

Barry BW. Drug delivery routes in skin: A novel approach. Adv Drug

Deliv Rev 2002;54:31-40.

Hadgraft J, Lane ME. Skin permeation: The years of enlightenment. Int

J Pharma 2005;305:2-12.

Foldvari M. Non-invasive administration of drugs through the skin:

challenges in delivery system design. PSTT 2000;3:417-25.

Madison KC. Barrier function of the Skin: ‘‘La Raison d’EOE tre’’ of the

Epidermis: A review. J Invest Dermatol 2003;121:231-41.

Murdan S. A review of pluronic lecithin organogel as a topical and

transdermal drug delivery system. Hosp Pharma 2005;12:267-70.

Franckum J, Ramsay D, Das NG, Das SK. Pluronic lecithin organogel

for local delivery of anti-inflammatory drugs. Int J Pharma Comp

;8:101-5.

Kumar R, Katare OP. Lecithin organogels as a potential phospholipid-

structured system for topical drug delivery: A review. AAPS Pharma Sci

Tech 2005;6:298-310.

The history of pluronic lecithin organogel: An interview with Marty

Jones. Int J Pharma Comp 2003;7:180-2.

Murdan S. Organogels in drug delivery. Exp Opin Drug Deliv

;2:489-505.

Willimann H, Walde P, Luisi PL, Gazzaniga A, Stroppolo F. Lecithin

organogels as matrix for transdermal transport of drugs. J Pharma Sci

;81:871-4.

Shchipunov YA. Lecithin organogel: A micellar system with unique

properties, colloids and surfaces. A Physicochemical and Engineering

Aspects. 2001. p. 183-5, 541-54.

Shchipunov YA, Shumilina EV. Lecithin bridging by hydrogen bonds in

the organogel. Mat Sci Engg 1995;C3:43-50.

Richards H, Thomas CP, Bowen JL, Heard CM. In-vitro transcutaneous

delivery of ketoprofen and polyunsaturated fatty acids from a pluronic

lecithin organogel vehicle containing fish oil. J Pharma Pharmacol

;58:903-8.

Ketoprofen 2.5 percent in pluronic lecithin organogel. Int J Pharma

Comp 1999;3:473.

Piroxicam 0.5 percent in pluronic lecithin organogel. Int J Pharma Comp 1999;3:133.

Ketoprofen 10 percent, cyclobenzaprine 1 percent and lidocaine 5 per

cent in pluronic lecithin organogel. Int J Pharma Comp 1998;2:154.

Hoffman SB, Trepanier LA, Yoder AR. Bioavailability of transdermal

methimazole in a pluronic lecithin organogel in healthy cats. J Vet

Pharmacol Ther 2002;25:89-93.

Willis-Goulet HS, Schmidt BA, Nicklin CF, Marsella R, Kunkle GA,

Tebbett IR. Comparison of serum dexamethasone concentrations in

cats after oral or transdermal administration using pluronic lecithin

organogel: A pilot study. Vet Dermatol 2003;14:83-9.

Steagall PV, Carnicelli P, Taylor PM, Luna SP, Dixon M, Ferreira TH.

Effects of subcutaneous methadone, morphine, buprenorphine or

saline on thermal and pressure thresholds in cats. J Vet Pharmacol Ther

;29:531-7.

Glisson JK, Wood RL, Kyle PB, Cleary JD. Bioavailability of promethazine

in a topical pluronic lecithin organogel: A pilot study. Int J Pharma Comp

;9:242-6.

Giordano J, Daleo C and Sacks SM. Topical ondansetron attenuates

nociceptive and inflammatory effects of intradermal capsaicin in

humans. Eur J Pharmacol 1998;354:13-4.

Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus

placebo: A double blind, randomized clinical trial in patients with

osteoarthritis of the knee. J Rheumatol 1999;26:2659-63.

Davidson G. Update on Transdermals for animal patients. Int J Pharma

Comp 2005;9:178-82.

Padilla M, Clark GT, Merrill RL. Topical medications for orofacial

neuropathic pain: A review. J Am Dent Assoc 2000;131:184-95.

Toney S, King E. Topically applied isophane insulin (NPH) in pluronic

lecithin organogel, RxTriad-Literature watch. Int J Pharma Comp 2001.

Most read articles by the same author(s)